Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and meta-analysis

被引:403
作者
Slimings, Claudia [1 ]
Riley, Thomas V. [1 ,2 ]
机构
[1] Univ Western Australia, Sch Pathol & Lab Med, Crawley, WA, Australia
[2] PathWest Lab Med WA, Nedlands, WA 6009, Australia
关键词
diarrhoea; antimicrobials; risk factors; healthcare facilities; RISK-FACTORS; FLUOROQUINOLONE USE; DIARRHEA; OUTBREAK; EPIDEMIOLOGY; EXPOSURE; DISEASE;
D O I
10.1093/jac/dkt477
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
To update the evidence for associations between antibiotic classes and hospital-acquired Clostridium difficile infection (HA-CDI). Electronic databases of journal articles, scholarly theses and conference proceedings using subject headings and keywords related to CDI and antibiotic exposure were searched. Observational epidemiological studies measuring associations between antibiotic classes and HA-CDI were eligible for inclusion. Pooled ORs and 95 CIs were calculated using a random effects model. Study factors identified a priori were examined as sources of heterogeneity. The quality of the studies was assessed using the Newcastle-Ottawa Scale. Of 569 citations identified, 13 casecontrol and 1 cohort study (15938 patients) were included. The strongest associations were found for third-generation cephalosporins (OR3.20, 95 CI1.805.71; n6 studies; I(2)79.2), clindamycin (2.86, 2.044.02; n6; I(2)28.5), second-generation cephalosporins (2.23, 1.473.37; n6; I(2)48.4), fourth-generation cephalosporins (2.14, 1.303.52; n2; I(2)0.0), carbapenems (1.84, 1.262.68; n6; I(2)0.0), trimethoprim/sulphonamides (1.78, 1.043.05; n5; I(2)70), fluoroquinolones (1.66, 1.172.35; n10; I(2)64) and penicillin combinations (1.45, 1.052.02; n6; I(2)54). The study population and the timing of measurement of antibiotic exposure were the most common sources of heterogeneity. Study quality scored high for seven studies, moderate for six studies and low for one study. The risk of HA-CDI remains greatest for cephalosporins and clindamycin, and their importance as inciting agents should not be minimized. The importance of fluoroquinolones should not be overemphasized, particularly if fluoroquinolone-resistant epidemic strains of C. difficile are absent.
引用
收藏
页码:881 / 891
页数:11
相关论文
共 36 条
[1]  
[Anonymous], 2010, SURGERY, DOI DOI 10.1016/J.SURG.2009.06.030
[2]  
[Anonymous], 2007, REV ESP GERIATR GERO
[3]  
[Anonymous], THESIS U ROCHESTER
[4]  
[Anonymous], THESIS U W AUSTR
[5]   Comparative analysis of prevalence, risk factors, and molecular epidemiology of antibiotic-associated diarrhea due to Clostridium difficile, Clostridium perfringens, and Staphylococcus aureus [J].
Asha, N. J. ;
Tompkins, D. ;
Wilcox, M. H. .
JOURNAL OF CLINICAL MICROBIOLOGY, 2006, 44 (08) :2785-2791
[6]   Case-control study of antibiotic use and subsequent Clostridium difficile -: Associated diarrhea in hospitalized patients [J].
Baxter, Roger ;
Ray, G. Thomas ;
Fireman, Bruce H. .
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 2008, 29 (01) :44-50
[7]   Meta-Analysis of Antibiotics and the Risk of Community-Associated Clostridium difficile Infection [J].
Brown, Kevin A. ;
Khanafer, Nagham ;
Daneman, Nick ;
Fisman, David N. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2013, 57 (05) :2326-2332
[8]   Clostridium difficile-Associated Infections in a Septic Ward of a Level 1 Trauma Centre: An Analysis of 159 Patients [J].
Citak, M. ;
Backhaus, M. ;
Dogan, A. ;
Aach, M. ;
Schildhauer, T. A. ;
Fehmer, T. .
ZEITSCHRIFT FUR ORTHOPADIE UND UNFALLCHIRURGIE, 2012, 150 (01) :62-66
[9]   Clinical Practice Guidelines for Clostridium difficile Infection in Adults: 2010 Update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA) [J].
Cohen, Stuart H. ;
Gerding, Dale N. ;
Johnson, Stuart ;
Kelly, Ciaran P. ;
Loo, Vivian G. ;
McDonald, L. Clifford ;
Pepin, Jacques ;
Wilcox, Mark H. .
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 2010, 31 (05) :431-455
[10]   METAANALYSIS IN CLINICAL-TRIALS [J].
DERSIMONIAN, R ;
LAIRD, N .
CONTROLLED CLINICAL TRIALS, 1986, 7 (03) :177-188